Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Eriksson

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
International Clinical Psychopharmacology|March 15, 2013
Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacyMichael E Thase, Stuart Montgomery, George I Papakostas, et al.
The Journal of Clinical Psychiatry|August 25, 2015
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind studyMichael E Thase, James M Youakim, Aleksandar Skuban, et al.
The Journal of Clinical Psychiatry|November 19, 2015
Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive DisorderSajjad A Khan, Dennis A Revicki, Mariam Hassan, et al.
The Journal of Clinical Psychiatry|August 25, 2015
Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressantsMichael E Thase, James M Youakim, Aleksandar Skuban, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 11, 2014
Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressantEduard Vieta, Michael E Thase, Dieter Naber, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Smart Program Design Through a Common Information ModelLaszlo Vasko, Mats Sundgren, Peter Bachmann, et al.
JMIR Mhealth and Uhealth|January 31, 2019
Barriers to and Facilitators of Engagement With mHealth Technology for Remote Measurement and Management of Depression: Qualitative AnalysisSara Simblett, Faith Matcham, Sara Siddi, et al.
Journal of Psychopharmacology (Oxford, England)|January 29, 2022
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparationJames J Rucker, Lindsey Marwood, Riikka-Liisa J Ajantaival, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
International Clinical Psychopharmacology|March 15, 2013
Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacyMichael E Thase, Stuart Montgomery, George I Papakostas, et al.
The Journal of Clinical Psychiatry|August 25, 2015
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind studyMichael E Thase, James M Youakim, Aleksandar Skuban, et al.
The Journal of Clinical Psychiatry|November 19, 2015
Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive DisorderSajjad A Khan, Dennis A Revicki, Mariam Hassan, et al.
The Journal of Clinical Psychiatry|August 25, 2015
Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressantsMichael E Thase, James M Youakim, Aleksandar Skuban, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 11, 2014
Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressantEduard Vieta, Michael E Thase, Dieter Naber, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Smart Program Design Through a Common Information ModelLaszlo Vasko, Mats Sundgren, Peter Bachmann, et al.
JMIR Mhealth and Uhealth|January 31, 2019
Barriers to and Facilitators of Engagement With mHealth Technology for Remote Measurement and Management of Depression: Qualitative AnalysisSara Simblett, Faith Matcham, Sara Siddi, et al.
Journal of Psychopharmacology (Oxford, England)|January 29, 2022
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparationJames J Rucker, Lindsey Marwood, Riikka-Liisa J Ajantaival, et al.
Pageof 6